

Supplemental Digital Content 6. Confirmed Virologic Withdrawals Through the Week 144 Analysis Window

Week of failure confirmation	Baseline CD4+ cell count, cells/mm ³	Time between SVW and CVW, day	Viral loads at baseline / SVW / CVW / and withdrawal, copies/mL	Resistance mutations		Fold change at baseline and CVW
				Baseline	SVW	
DTG + 3TC						
Week 16	212	7	124,492 / 6648 / 56,435 / 95	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.67, 0.72 3TC, 1.13, 1.12
Week 24	284	28	50,263 / 348 / 206 / 96	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.76, 0.7 3TC, 0.98, 0.69
Week 24	19	23	368,439 / 212 / 376 / 362	NRTI: none INSTI: G193G/E	NRTI: none INSTI: none	DTG, 0.88, 0.86 3TC, 1.02, 1.43
Week 24	213	27	96,277 / 451 / 9602 / 67	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.92, 0.8 3TC, 1.16, 1.16
Week 24	529	34	17,232 / 461 / 251 / 59	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.81, 0.87 3TC, 1.17, 1.09
Week 48	414	22	37,701 / 43,908 / 38,457 ^a	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.8, 0.79 3TC, 0.9, 1.74
Week 60	347	101	101,671 / 703 / 85,556 ^a	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.89, 1.13 3TC, 0.95, 0.87
Week 60	567	21	7654 / 3972 / 3131 / 1513	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.7, 0.71 3TC, 0.86, 0.86
Week 72	50	14	63,817 / 422 / 2154 / 115	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.64, 0.81 3TC, 0.84, 0.69
Week 72	74	27	112,812 / 61,076 / 87,794 / 671	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.84, 0.9 3TC, 0.84, 0.73
Week 108	317	31	341,818 / 396 / 726 / 280	NRTI: none INSTI: L74I	NRTI: none INSTI: L74I	DTG, 0.72, 0.83 3TC, 1.09, 1.04
Week 120	235	29	370,321 / 1041 / 713 / <40	NRTI: none INSTI: G193E	NRTI: none INSTI: G193E	DTG, 0.91, 1.08 3TC, 0.84, 0.91
DTG + TDF/FTC						
Week 12	22	28	136,753 / 393 / 276 ^b	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.95, 1.03 TDF, 0.98, 0.99

Week 24	226	27	10,930 / 1136 / 809 / 264	NRTI: none INSTI: none	NRTI: none INSTI: none	FTC, 0.86, 1.10 DTG, 0.72, NR TDF, 1, 0.81 FTC, 0.92, 0.95
Week 24	251	30	76,325 / 569 / 362 / <50	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 0.68, 1.38 TDF, 0.95, 0.61 FTC, 1.13, 0.67
Week 24	201	28	156,701 / 213 / 1559 / 97	NRTI: none INSTI: none	NRTI: none INSTI: NR	DTG, 0.9, NR TDF, 1.04, 1.07 FTC, 0.97, 1.01
Week 48	602	83	1568 / 8384 / 3653 / 3011	NRTI: K70K/E INSTI: G193E	NRTI: none INSTI: G193G/E	DTG, 1.05, 1.05 TDF, 0.76, 0.77 FTC, 1.14, 1.28
Week 72	253	16	668,811 / 254 / 232 / 121	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 1.13, NR TDF, 0.71, NR FTC, 0.68, NR
Week 96	144	40	28,905 / 30,316 / 7793 ^a	NRTI: none INSTI: L74I	NRTI: none INSTI: L74I	DTG, 0.68, 0.78 TDF, 0.82, 0.82 FTC, 1.07, 0.95
Week 108	524	24	9341 / 873 / 1728 / 657	NRTI: none INSTI: NR	NRTI: none INSTI: NR	DTG, NR, NR TDF, 0.63, 0.64 FTC, 0.74, 0.68
Week 132	121	26	27,227 / 214 / 213 / <40	NRTI: none INSTI: none	NRTI: none INSTI: none	DTG, 1.02, 0.95 TDF, 0.86, 0.76 FTC, 0.86, 1.14

CVW, confirmed virologic withdrawal; DTG, dolutegravir; FTC, emtricitabine; INSTI, integrase strand transfer inhibitor; NR, not reported because of assay failure; NRTI, nucleoside reverse transcriptase inhibitor; SVW, suspected virologic withdrawal; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.

^aParticipant met CVW at the withdrawal visit; no subsequent visit occurred. ^bParticipant met the criteria for CVW at Week 12 but was not reported at the Week 48 analysis because of a laboratory reporting error identified after the Week 48 analysis. This participant was not withdrawn as per protocol at the time and has been allowed to continue in the study (the participant has maintained virologic suppression from Week 24 through Week 132, met SVW criteria at Week 144, and was re-suppressed upon re-testing).